Molecular alterations in lung cancer. Impact on prognosis.
There are multiple molecular abnormalities that can occur in lung cancer. Based on the aberrancies described previously, many investigators and drug companies are designing novel therapies. The molecular markers can also be used as prognostic variables for future clinical trials and therapeutic interventions. It will not be an easy task to make an impact on lung cancer using these methods, since multiple pathways are abnormal in its pathogenesis. It is hoped that with the advent of novel and directed therapeutics, we may soon show some impact on the survival of this devastating disease.
Kijima
Takashi
T
Division of Adult Oncology and Thoracic Oncology Program, Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Maulik
Gautam
G
Salgia
Ravi
R
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002869:Chromosome Aberrations; D004195:Disease Models, Animal; D016147:Genes, Tumor Suppressor; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D051379:Mice; D008967:Molecular Biology; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D019098:Telomerase / Q000378:metabolism
D011518:Proto-Oncogene Proteins; D019098:Telomerase